Back to Search
Start Over
Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in <scp>ADAMTS13</scp> activity
Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in <scp>ADAMTS13</scp> activity
- Source :
- Transfusion. 60:1308-1318
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background Increases in plasma von Willebrand Factor (VWF) levels, accompanied by decreases in the metalloprotease ADAMTS13, have been demonstrated soon after traumatic injury while downstream effects remain unclear. Study design and methods A cohort of 37 injured trauma patients from a randomized control trial investigating the use of prehospital plasma transfusion were analyzed for activity and antigen levels of ADAMTS13 and VWF at 0 and 24 hours after admission. Relevant clinical data were abstracted from the medical records. Trauma patient plasma was analyzed via agarose gel electrophoresis to evaluate the effects of injury on VWF multimer composition compared to healthy controls. Results von Willebrand factor levels were elevated at presentation (189% [110%-263%] vs. 95% [74%-120%]), persisting through 24 hours (213% [146%-257%] vs. 132% [57%-160%]), compared to healthy controls. Ultralarge VWF (UL-VWF) forms were elevated in trauma patients at both 0 and 24 hours, when compared to pooled normal plasma (10.0% [8.9%-14.3%] and 11.3% [9.1%-21.2%], respectively, vs. 0.6%). Circulating plasma ADAMTS13 activity was decreased at 0 hours (66% [47%-86%] vs. 100% [98%-100%]) and at 24 hours (72.5% [56%-87.3%] vs. 103% [103%-103%]) in trauma patients. ADAMTS13 activity independently predicted the development of coagulopathy and correlated with international normalized ratio, thromboelastography values, injury severity, and blood product transfusion. Conclusion Traumatic injury is associated with acute coagulopathy that is characterized by increased UL-VWF multimers and reduction in ADAMTS13, which correlates with blood loss, transfusion requirement, and injury severity. These findings suggest the potential for future trials targeting ADAMTS13 repletion to enhance clearance of VWF multimers.
- Subjects :
- Adult
Male
medicine.medical_specialty
Time Factors
Immunology
ADAMTS13 Protein
Blood Component Transfusion
030204 cardiovascular system & hematology
Gastroenterology
law.invention
Plasma
03 medical and health sciences
0302 clinical medicine
Von Willebrand factor
Randomized controlled trial
Blood product
law
hemic and lymphatic diseases
Internal medicine
von Willebrand Factor
medicine
Coagulopathy
Humans
Immunology and Allergy
Trauma Severity Indices
biology
medicine.diagnostic_test
business.industry
Hematology
Middle Aged
medicine.disease
Thromboelastography
ADAMTS13
Traumatic injury
Cohort
biology.protein
Wounds and Injuries
Female
business
030215 immunology
Subjects
Details
- ISSN :
- 15372995 and 00411132
- Volume :
- 60
- Database :
- OpenAIRE
- Journal :
- Transfusion
- Accession number :
- edsair.doi.dedup.....2590b7ad106ed086a73f2d58bd84ad31
- Full Text :
- https://doi.org/10.1111/trf.15856